Emflaza® (deflazacort) – Expanded indication
June 7, 2019 - PTC Therapeutics announced the FDA approval of Emflaza (deflazacort) tablets and oral suspension for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
Download PDF
